For MZ SR:
- Director-General Department of Pharmacy and Drug Policy MUDr. Adam Hlôška
- Director of the Department of Classification, Pricing and Drug Policy PharmDr. Rastislav Pullmann
- Officer of the Department of Classification, Pricing and Drug Policy of MVDr. Erika Hanzelyová
For GSK:
- MUDr. Pavol Trnovec
The meeting took place at the request of the representative of GSK MUDr. Trnovec.
The meeting was opened by the Director General of the Department of Pharmacy and Drug Policy MUDr. Adam Hlôška.
GSK:
The reason for requesting a meeting is to alert GSK to the fact that there might be insufficient quantity of Priorix on the Slovak market, as there are differences in consumption data according to the NCZ and the quantity of sales of the product in question to the distribution.
GSK warns MZ SR about the need to verify these data and, if confirmed, to consider further steps to ensure the availability of vaccines in the paper vaccination for insured persons under the current legislation.
In no way does GSK interfere with the commercial relations of distributors and pharmacies.
MZ SR:
SUKL can only issue a re-export ban decision in the light of the legislation in force. The Ministry expects GSK to provide information on the sale of the medicinal product to specific distribution companies. The Ministry will continue to act on this information.
The meeting was concluded by the Director General of the Department of Pharmacy and Drug Policy MUDr. Adam Dormouse
Signed by: MVDr. Erika Hanzely
Verified for GSK: MUDr. Pavol Trnovec
Approval: MUDr. Adam Hlôška